The future of monoclonal antibody technology.
With the rapid growth of monoclonal antibody-based products, new technologies have emerged for creating modified forms of antibodies, including fragments, conjugates and multi-specific antibodies. We created a database of 450 therapeutic antibodies in development to determine which technologies and indications will constitute the "next generation" of antibody products. We conclude that the antibodies of the future will closely resemble the antibodies that have already been approved for commercial sale.
Zider
Alexander
A
Tufts University School of Medicine.
Drakeman
Donald L
DL
Advent Venture Partners.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000302:isolation & purification* / Q000627:therapeutic use; D000918:Antibody Specificity; D001702:Biopharmaceutics / Q000639:trends*; D062313:Databases, Pharmaceutical; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use; D062069:Inventions / Q000706:statistics & numerical data; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000302:isolation & purification / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D011993:Recombinant Fusion Proteins